Get started

Financials · ATYR

aTyr Pharma Inc. (ATYR) financials

For fiscal 2025 (ended Dec 31, 2025), aTyr Pharma Inc. reported $190.0K of revenue and -$74.12M of net income.

Revenue, FY2025
$190.0K
Revenue growth, YoY
-19.1%
Net income, FY2025
-$74.12M
Net margin
-39009.5%
Free cash flow, FY2025
-$62.06M
EPS, diluted, FY2025
-$32.00
Cash
$13.14M
P/S
83.97
Market cap
$16.0M
Annual revenue$190.0K
FY2019FY2025
Annual net income-$74.12M
FY2016FY2025
Annual free cash flow-$62.06M
FY2016FY2025

ATYR revenue and earnings growth

ATYR revenueQ3 2026$0

Quarter YoY
-100.0%
FY YoY
-19.1%
5Y CAGR
-55.1%

ATYR revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), down 100.0% from a year earlier. For the full fiscal 2025 it was $190.0K, down 19.1% from fiscal 2024. Compound annual growth was -55.1% over 5 years. It rose in 0 of the last 3 fiscal years.

ATYR net incomeQ3 2026-$18.26M

ATYR net income was -$18.26M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$25.74M a year earlier. For the full fiscal 2025 it was -$74.12M, compared with -$64.02M in fiscal 2024.

ATYR EPSQ3 2026-$7.43

ATYR diluted EPS was -$7.43 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$10.60 a year earlier. For the full fiscal 2025 it was -$32.00, compared with -$34.40 in fiscal 2024.

ATYR free cash flowQ3 2026-$9.56M

ATYR free cash flow was -$9.56M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$20.51M a year earlier. For the full fiscal 2025 it was -$62.06M, compared with -$69.18M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$190.0K$235.0K$353.0K$10.39M$0$10.46M$422.0K---
Research and development$60.22M$54.37M$42.29M$42.81M$23.26M$17.29M$14.05M$20.39M$30.07M$42.85M
Selling, general and admin$17.60M$13.78M$12.98M$13.98M$10.75M$9.07M$9.35M$12.44M$17.08M$15.09M
Operating income-$77.63M-$67.91M-$54.92M-$46.40M-$34.02M-$15.91M-$22.98M-$32.82M-$47.15M-$57.94M
Pre-tax income-$74.12M-$64.02M-$50.40M-$45.34M-$33.77M-$16.23M-$23.76M-$34.52M-$48.21M-$57.90M
Income tax$0$0$0$0$0$0$0$0--$49.0K
Net income-$74.12M-$64.02M-$50.39M-$45.34M-$33.77M-$16.22M-$16.22M-$34.52M-$48.21M-$57.85M
EPS, basic-$32.00-$34.40-$37.60-$64.00-$70.80-$70.80-$281.20-$644.40-$1045.20-$1366.40
EPS, diluted-$32.00-$34.40-$37.60-$64.00-$70.80-$70.80-$281.20-$644.40-$1045.20-$1366.40
Diluted shares2.3M1.9M1.3M710,489.225477,021.95229,006.72583,89053,549.02546,125.82542,287.534

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$10.74M$11.05M$22.54M$9.98M$2.34M$16.95M$9.21M$22.96M$21.09M$38.39M
Current assets$80.24M$81.95M$102.99M$80.87M$113.57M$35.53M$31.93M$50.80M$86.98M$74.77M
Total assets$93.00M$96.83M$120.65M$95.79M$115.54M$38.73M$36.19M$52.75M$89.36M$80.52M
Current liabilities$15.15M$14.97M$16.42M$13.86M$6.01M$5.86M$12.92M$10.83M$10.39M$8.53M
Short-term debt------$8.74M$7.77M$5.01M$339.0K
Long-term debt-------$8.26M$14.72M$9.20M
Total debt-------$16.03M$19.73M$9.54M
Total liabilities$25.71M$27.00M$30.18M$24.50M$6.41M$7.24M$15.16M$19.10M--
Shareholders' equity$67.48M$69.83M$90.47M$71.28M$109.13M$31.48M$21.03M$33.65M$64.25M$62.80M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$61.99M-$69.12M-$33.22M-$41.89M-$33.08M-$15.30M-$20.01M-$31.06M-$42.36M-$52.86M
Capital expenditures$77.0K$65.0K$4.21M$1.64M$192.0K$202.0K$79.0K$594.0K$1.31M$600.0K
Free cash flow-$62.06M-$69.18M-$37.44M-$43.53M-$33.27M-$15.50M-$20.09M-$31.66M-$43.68M-$53.46M
Investing cash flow-$5.05M$17.23M-$20.13M$47.24M-$91.57M$6.90M$4.92M$37.17M-$27.64M$33.53M
Financing cash flow$66.01M$39.86M$66.23M$5.45M$110.03M$16.14M$1.34M-$4.24M$52.70M$4.70M
Depreciation and amortization$664.0K$708.0K$592.0K$232.0K$475.0K$569.0K$635.0K$746.0K$713.0K$900.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-19.1%-33.4%-96.6%--100.0%2377.5%----
Operating margin-40856.3%-28899.6%-15557.8%-446.8%--152.2%-5445.0%---
Net margin-39009.5%-27243.8%-14274.5%-436.5%--155.2%-3844.5%---
Free cash flow margin-32664.7%-29440.0%-10605.1%-419.1%--148.3%-4761.1%---
Return on equity-109.8%-91.7%-55.7%-63.6%-30.9%-51.5%-77.2%-102.6%-75.0%-92.1%
Return on assets-79.7%-66.1%-41.8%-47.3%-29.2%-41.9%-44.8%-65.4%-53.9%-71.8%
Current ratio5.305.486.275.8318.896.062.474.698.378.77
Debt to equity-------0.480.310.15

Source: XBRL data aTyr Pharma Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-14, first reported Aug 14, 2019; 1-for-40, first reported Nov 6, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ATYR peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ATYR$190.0K-19.1%-$74.12M-39009.5%$16.0M
AMGN$38.90B+8.2%$9.39B24.1%$249.05B
GILD$30.99B+6.5%-$3.86B-12.5%$207.00B
MRNA$2.52B+13.1%-$2.79B-110.5%$101.48B
ARGX$4.25B+88.6%$1.29B30.4%$57.55B
RVMD$0--$1.13B-$41.59B
BIIB$10.30B+2.3%$347.50M3.4%$36.71B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$16.98B

ATYR FAQ

8 questions
  • What is ATYR revenue?
    aTyr Pharma Inc. (ATYR) reported $190.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 19.1% from the year before.
  • Is ATYR profitable?
    No. aTyr Pharma Inc. reported a net loss of $74.12M for fiscal 2025 (ended Dec 31, 2025).
  • How much cash and debt does ATYR have?
    aTyr Pharma Inc. reported $13.14M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ATYR revenue growing?
    aTyr Pharma Inc.'s revenue changed -19.1% in fiscal 2025, to $190.0K. Its compound annual growth rate was -55.1% over 5 years.
  • What is ATYR free cash flow?
    aTyr Pharma Inc. generated -$62.06M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$61.99M less capital expenditures.
  • What is ATYR earnings per share?
    Diluted earnings per share were -$32.00 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.
  • When did ATYR last report financial results?
    The latest statements here come from aTyr Pharma Inc.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.
  • Where does this ATYR financial data come from?
    Quantisnow builds these statements from the structured XBRL data aTyr Pharma Inc. files with the SEC. It is provided for information only and is not investment advice.